Walleye Capital
SLNO

Walleye Capital’s Soleno Therapeutics SLNO Stock Holding History

Walleye Capital’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,983
Closed -$786K – 4947
2025
Q4 		$786K Buy
16,983
+16,242
+2,192% +$891K ﹤0.01% 2628
2025
Q3 		$50.1K Buy
741
+568
+328% +$42.1K ﹤0.01% 3998
2025
Q2 		$14.5K Sell
173
-97,363
-100% -$7.29M ﹤0.01% 4276
2025
Q1 		$6.97M Buy
97,536
+20,602
+27% +$1M 0.03% 606
2024
Q4 		$3.46M Buy
+76,934
New +$3.99M 0.01% 1331
2023
Q4 		– Sell
-46,244
Closed -$1.36M – 5463
2023
Q3 		$1.36M Buy
+46,244
New +$280K ﹤0.01% 2017

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Walleye Capital's SLNO Position: Q1 2026 in Review

Walleye Capital sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 16,983 shares — an estimated $786K sold.

Walleye Capital first reported a position in SLNO in Q3 2023 and held it in 6 quarters. The position peaked at $6.97M in Q1 2025. 226 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Walleye Capital reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 16,983 Soleno Therapeutics shares in Q1 2026, an estimated $786K.
  • Walleye Capital first reported a position in Soleno Therapeutics in Q3 2023 and held it in 6 quarters.
  • Walleye Capital's Soleno Therapeutics position peaked at $6.97M in Q1 2025.
  • 226 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.